Non-small cell lung carcinoma, Cancer, Solid tumor/s
IPHAInnate Pharma SACatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Monalizumab + durvalumab + oleclumab in Non-small cell lung carcinoma, Cancer, Solid tumor/s. The expected timing is based on the latest available company guidance and may change.
Collab w/ AstraZeneca. Presented interim Ph2 NeoCOAST data at ESMO 2021 on 9/17/21. Currently progressing in Ph3 PACIFIC-9 trial. Presentations at ASCO '23. 11/14/23- Trial progressing. Updated COAST study data at ASCO '24. 9/9/24- Presented interim data at WCLC '24. 11/12/25:- Ph3 PACIFIC-9 enrollment complete; data readout expected in H2 2026. 03/25/26:- PACIFIC-9 Ph3 NSCLC trial with monalizumab continues; H2 2026 data readout expectation reiterated. 05/12/26:- PACIFIC-9 Ph3 NSCLC trial enrollment complete; data readout remains expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.